title: Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes.
abstract: OBJECTIVE
  To evaluate long-term effects of continuous glucose monitoring (CGM) in intensively treated adults with type 1 diabetes.
  
  
  METHODS
  We studied 83 of 86 individuals >or=25 years of age with type 1 diabetes who used CGM as part of a 6-month randomized clinical trial in a subsequent 6-month extension study. RESULTS After 12 months, median CGM use was 6.8 days per week. Mean change in A1C level from baseline to 12 months was -0.4 +/- 0.6% (P < 0.001) in subjects with baseline A1C >or=7.0%. A1C remained stable at 6.4% in those with baseline A1C <7.0%. The incidence rate of severe hypoglycemia was 21.8 and 7.1 events per 100 person-years in the first and last 6 months, respectively. Time per day with glucose levels in the range of 71-180 mg/dl increased significantly (P = 0.02) from baseline to 12 months.
  
  
  CONCLUSIONS
  In intensively treated adults with type 1 diabetes, CGM use and benefit can be sustained for 12 months.
authors.forename: Bruce
authors.initials: B
authors.lastname: Bode
authors.forename: Roy W
authors.initials: RW
authors.lastname: Beck
authors.forename: Dongyuan
authors.initials: D
authors.lastname: Xing
authors.forename: Lisa
authors.initials: L
authors.lastname: Gilliam
authors.forename: Irl
authors.initials: I
authors.lastname: Hirsch
authors.forename: Craig
authors.initials: C
authors.lastname: Kollman
authors.forename: Lori
authors.initials: L
authors.lastname: Laffel
authors.forename: Katrina J
authors.initials: KJ
authors.lastname: Ruedy
authors.forename: William V
authors.initials: WV
authors.lastname: Tamborlane
authors.forename: Stuart
authors.initials: S
authors.lastname: Weinzimer
authors.forename: Howard
authors.initials: H
authors.lastname: Wolpert
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis* / Q000378:metabolism; D001835:Body Weight; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000523:psychology; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000175:diagnosis; D007003:Hypoglycemia / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D018670:Monitoring, Ambulatory / Q000379:methods*; D009042:Motivation; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin
references.citation: N Engl J Med. 1993 Sep 30;329(14):977-86
references.pmid: 8366922
references.citation: N Engl J Med. 2008 Oct 2;359(14):1464-76
references.pmid: 18779236
references.citation: Clin Chem. 1999 Oct;45(10):1833-41
references.pmid: 10508131
references.citation: Diabetes. 1993 Nov;42(11):1683-9
references.pmid: 8405713
references.citation: Diabetes Care. 2009 Aug;32(8):1378-83
references.pmid: 19429875
references.citation: Diabetes Care. 1997 Nov;20(11):1655-8
references.pmid: 9353603
references.citation: Diabetes Technol Ther. 2008 Aug;10(4):310-21
references.pmid: 18828243
references.citation: Am J Med. 1991 Apr;90(4):450-9
references.pmid: 2012085